pH 5.0
Sponsors
Philipps-Universitaet Marburg, Apellis Pharmaceuticals Inc.
Conditions
Focal segmental glomerulosclerosis (FSGS)Progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia
Phase 2
Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia - A prospective two-armed, phase II clinical multicentre randomized, placebo-controlled (2:1), blinded with open-label extension trial (TEFIBEOS)
RecruitingCTIS2024-510884-51-00
Start: 2025-06-09Target: 39Updated: 2025-11-12
A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis
Not yet recruitingCTIS2025-524448-36-00
Target: 71Updated: 2026-07-15